Switching to Insulin Degludec from Insulin Glargine U100 Improves Glycemic Control in People with Type 1 (T1D) or Type 2 diabetes (T2D) in a Real-World Setting
Authors: KNUDSEN SOREN T. , TENTOLOURIS NIKOLAOS , SCHULTES BERND , LAPOLLA ANNUNZIATA , EIDENMUELLER MARKUS , PRAGER RUDOLF , CATARIG ANDREI-MIRCEA , WOLDEN MICHAEL L. , SIEGMUND THORSTEN 
Published: June 2018

EU-TREAT (NCT02662114), a European, multicenter, retrospective chart review study investigated the clinical impact of switching from any basal insulin to insulin degludec (degludec). This analysis aimed to evaluate the effectiveness of degludec after switching from insulin glargine 100 units/mL (glargine U100), under routine care. Patients with T1D or T2D were switched, based on clinical judgement, from glargine U100 to degludec at least 6 months before data collection. Baseline was defined as the most recent recording during the 3-months pre-switch period. Outcome data were collected at 6 ± 3 months and at 12 ± 3 months pre- and post-switch. BothHbA1c and fasting plasma glucose (FPG) decreased significantly in patients with T1D (n=889) or T2D (n=259) at 6- and 12-months post-switch vs. pre-switch (all p&lt;0.001, except for FPG at 12-months post-switch in T2D, p=0.023). Daily insulin dose decreased significantly in patients with T1D at 6- and 12-months post-switch vs. pre-switch (both p&lt;0.001), but remained unchanged in patients with T2D. Hypoglycemia was significantly lower (all p&lt;0.05) post-switch vs. pre-switch (Figure). Switching to degludec from glargine U100 significantly reduces HbA1c and risk of hypoglycemia under routine care.

Disclosure
S.T. Knudsen: Advisory Panel; Self; Novo Nordisk A/S, Merck & Co., Inc., Sanofi-Aventis, Eli Lilly and Company, Boehringer Ingelheim GmbH, AstraZeneca. Speaker's Bureau; Self; Merck & Co., Inc., Boehringer Ingelheim GmbH, AstraZeneca. N. Tentolouris: Advisory Panel; Self; MSD K.K., AstraZeneca, Sanofi, Novo Nordisk A/S, Elpen Pharmaceutical Co. Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, Novartis AG. Research Support; Self; MSD K.K., Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Pfizer Inc., AstraZeneca, Janssen-Cilag Pty Limited, GlaxoSmithKline plc., Novartis AG. B. Schultes: Advisory Panel; Self; Novo Nordisk A/S, Sanofi, AstraZeneca, Eli Lilly and Company, Bayer AG, Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Sanofi, Eli Lilly and Company, MSD K.K., Bayer AG, Boehringer Ingelheim GmbH. A. Lapolla: None. M. Eidenmueller: Research Support; Self; Novo Nordisk A/S, Sanofi, AstraZeneca. Speaker's Bureau; Self; Berlin-Chemie AG. R. Prager: Advisory Panel; Self; Novo Nordisk A/S, Eli Lilly and Company, MSD K.K., Sanofi-Aventis, Boehringer Ingelheim GmbH, AstraZeneca. A. Catarig: Employee; Self; Novo Nordisk Region Europe Pharmaceuticals A/S. Employee; Spouse/Partner; GlaxoSmithKline plc. M.L. Wolden: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. T. Siegmund: Advisory Panel; Self; Abbott, Ascensia Diabetes Care, Bayer Vital GmbH, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen, Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Becton, Dickinson and Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Abbott, AstraZeneca, Bristol-Myers Squibb Company, Berlin-Chemie AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Sanofi.